Condition

Refractory Acute Myeloid Leukemia clinical trials and research

• 40Clinical trials
• 3NIH research projects
• 3Countries

Newest Refractory Acute Myeloid Leukemia clinical trials

All recruiting trials (40)

• CRD3874-SI in People with Leukemia

  A small early-stage study tests CRD3874-SI to see if it is safe for adults with relapsed or refractory acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07661095

• Total marrow and lymphoid irradiation with fludarabine and melphalan for older adults with refractory/relapsed AML or high-risk MDS undergoing donor stem cell transplant

  This phase 2 trial tests a targeted radiation conditioning (TMLI) with fludarabine and melphalan before a matched donor stem cell transplant in people aged 50 or older with difficult-to-treat AML or high-risk MDS.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07582172

• LILRA6 CAR-T therapy for relapsed or refractory acute myeloid leukemia.

  This trial will test LILRA6-directed CAR-T cell therapy to see if it helps adults (18–75) whose acute myeloid leukemia has returned or not responded to prior treatments.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07263906

• MiRisten to treat relapsed or refractory acute myeloid leukemia

  This phase 1 trial tests whether intravenous miRisten, a miR-126 inhibitor, is safe and tolerable and may help adults with relapsed or refractory acute myeloid leukemia.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07025564

• WBC100 capsules for adults with relapsed or refractory acute myeloid leukemia

  This trial will test whether taking WBC100 capsules once daily is safe and can help induce remission in adults with relapsed or refractory acute myeloid leukemia.

  Recruiting Phase 1 Hangzhou Weben Pharma Co., Ltd · Hangzhou, Zhejiang · NCT07014449

• Cedazuridine/decitabine with filgrastim dose escalation after stem cell transplant for children with high-risk AML

  This phase 1 trial will test whether giving the oral combination cedazuridine/decitabine (ASTX727) together with filgrastim is safe and find the highest tolerable dose for children with high-risk acute myeloid leukemia after allogeneic stem cell transplant.

  Recruiting at 14 sites Phase 1 National Cancer Institute (NCI) · Birmingham, Alabama and 14 other locations · NCT07012044

• Decitabine plus FLAG‑Ida chemotherapy and total‑body irradiation before donor stem cell transplant for adults with high‑risk myeloid cancers

  This test tries whether adding decitabine to FLAG‑Ida chemotherapy and total‑body irradiation before a donor stem cell transplant helps adults with high‑risk or relapsed myeloid blood cancers live longer and stay in remission.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06928662

• CD83-targeted CAR T cell therapy for adults with relapsed or refractory acute myeloid leukemia

  This Phase 1 trial tests a personalized CD83-targeted CAR T-cell infusion to try to eliminate leukemia cells in adults whose AML has relapsed or not responded to prior treatment.

  Recruiting Phase 1 Roswell Park Cancer Institute · Buffalo, New York · NCT06871410

• New treatment for patients with relapsed acute myeloid leukemia

  This study is testing a new treatment called CER-1236 to see if it can help people with relapsed acute myeloid leukemia feel better and improve their chances of recovery.

  Recruiting at 5 sites Phase 1 CERo Therapeutics Holdings, Inc. · Sacramento, California and 4 other locations · NCT06834282

• AOH1996 in relapsed/refractory AML: finding a safe dose

  This early-phase study tests whether AOH1996 can be given safely to adults with relapsed or refractory AML and what dose works best.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06763341

• Evaluating a new chemotherapy regimen for relapsed or refractory AML

  This study is testing a new combination of chemotherapy drugs to see if it can help people with acute myeloid leukemia that hasn't responded to other treatments.

  Recruiting Phase 2 Beijing 302 Hospital · Beijing · NCT06741722

• Combining tagraxofusp with low-intensity chemotherapy for treating specific types of leukemia

  This study is testing a new treatment combining tagraxofusp with low-intensity chemotherapy to see if it helps people with certain types of leukemia that haven't responded to previous treatments.

  Recruiting Phase 1/2 Stanford University · Palo Alto, California · NCT06561152

• Combining PD-1 inhibitor with venetoclax for treating tough cases of leukemia and myelodysplastic syndromes

  This study is testing a new treatment that combines three drugs to see if it can help people with tough cases of leukemia and myelodysplastic syndromes who haven't responded to other treatments.

  Recruiting Phase 2 Beijing 302 Hospital · Beijing, Beijing Municipality · NCT06536959

• Testing BH-30236 for relapsed or refractory acute myelogenous leukemia and higher-risk myelodysplastic syndrome

  This study is testing a new drug called BH-30236 to see if it can help adults with relapsed or hard-to-treat acute myelogenous leukemia or higher-risk myelodysplastic syndrome.

  Recruiting at 13 sites Phase 1 BlossomHill Therapeutics · Duarte, California and 12 other locations · NCT06501196

• Testing a new anti-cancer drug for patients with acute myeloid leukemia and myelodysplastic syndromes

  This study is testing a new anti-cancer drug called cirtuvivint, alone and with another drug, to see if it helps people with acute myeloid leukemia and myelodysplastic syndromes feel better and live longer.

  Recruiting at 20 sites Phase 1 National Cancer Institute (NCI) · New Haven, Connecticut and 22 other locations · NCT06484062

• Comparing high and low intensity therapies for relapsed or refractory acute myeloid leukemia

  This study is testing whether high-intensity or low-intensity therapies work better for adults with relapsed or hard-to-treat acute myeloid leukemia who are getting ready for a stem cell transplant.

  Recruiting Phase 3 National Research Center for Hematology, Russia · Moscow · NCT06418776

• Combining eltanexor and venetoclax for treating relapsed or refractory blood cancers

  This study is testing a new combination of two medications, eltanexor and venetoclax, to see if they can help people with relapsed or hard-to-treat blood cancers like myelodysplastic syndrome and acute myeloid leukemia.

  Recruiting at 2 sites Phase 1 Vanderbilt-Ingram Cancer Center · Memphis, Tennessee and 1 other locations · NCT06399640

• Combination treatment for relapsed or refractory acute myeloid leukemia with specific mutations

  This study is testing a new combination of two drugs for people with relapsed or hard-to-treat acute myeloid leukemia that has specific gene mutations to see if it helps them feel better.

  Recruiting at 4 sites Phase 1 Ohio State University Comprehensive Cancer Center · Chapel Hill, North Carolina and 3 other locations · NCT06222580

• Combining revumenib, azacitidine, and venetoclax for treating pediatric and young adult patients with tough cases of acute myeloid leukemia

  This study is testing a new combination of drugs to see if it can help young patients with tough cases of acute myeloid leukemia feel better and achieve remission.

  Recruiting at 10 sites Phase 1 St. Jude Children's Research Hospital · San Diego, California and 9 other locations · NCT06177067

• Using CAR T cells to treat acute myeloid leukemia

  This study is testing a new treatment using specially modified CAR T cells to see if it can safely help adults and kids with tough cases of acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06017258

• CAR T Cell Therapy for Recurrent or Refractory Acute Myeloid Leukemia

  This study is testing a new CAR T-cell therapy to see if it can help people with recurring or hard-to-treat acute myeloid leukemia by using modified immune cells to attack cancer cells.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT05672147

• Combining new drugs with chemotherapy for relapsed or refractory acute myeloid leukemia

  This study is testing if adding new drugs, palbociclib or tazemetostat, to standard chemotherapy can help people with relapsed or refractory acute myeloid leukemia feel better and fight their cancer more effectively.

  Recruiting Phase 1 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT05627232

• Venetoclax plus bomedemstat for relapsed or refractory acute myeloid leukemia

  This trial tests whether giving bomedemstat together with venetoclax is safe and tolerable for adults whose acute myeloid leukemia has relapsed or not responded to prior treatment.

  Recruiting Phase 1 University of Miami · Miami, Florida · NCT05597306

• Combination treatment for FLT3-mutated acute myeloid leukemia and high-risk myelodysplastic syndrome

  This study is testing a new combination of three drugs to see if it can help people with FLT3-mutated acute myeloid leukemia or high-risk myelodysplastic syndrome feel better and live longer.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT05010122

• Combining decitabine/cedazuridine and venetoclax with ivosidenib or enasidenib for treating relapsed or refractory acute myeloid leukemia

  This study is testing a new combination treatment for people with relapsed or refractory acute myeloid leukemia to see if it helps them respond better to therapy.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT04774393

• Combining CPX-351 and ivosidenib for treating IDH1 mutated acute myeloid leukemia and high-risk myelodysplastic syndrome

  This study is testing a combination of two treatments, CPX-351 and ivosidenib, to see if they can help people with acute myeloid leukemia or high-risk myelodysplastic syndrome who have an IDH1 mutation.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04493164

• Chemotherapy and Stem Cell Transplant for Relapsed or Refractory Blood Cancers

  This study is testing a combination of two chemotherapy treatments and total body radiation to see if it helps people with relapsed or hard-to-treat blood cancers get ready for a stem cell transplant.

  Recruiting Phase 1 Fred Hutchinson Cancer Center · Seattle, Washington · NCT04375631

• Combining azacitidine, venetoclax, and gilteritinib for treating FLT3-mutated blood cancers

  This study is testing a new combination of three medications to see if they can help people with certain types of blood cancers that have a specific genetic mutation.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT04140487

• Using Vyxeos to treat acute myeloid leukemia patients with persistent disease after initial chemotherapy

  This study is testing if a new treatment called Vyxeos can help people with acute myeloid leukemia who didn't get better with standard chemotherapy.

  Recruiting Phase 1/2 Ohio State University Comprehensive Cancer Center · Sacramento, California and 1 other locations · NCT04049539

• Combining cladribine, idarubicin, cytarabine, and quizartinib for treating acute myeloid leukemia and high-risk myelodysplastic syndrome

  This study is testing a new combination of four drugs to see if it can help people with acute myeloid leukemia or high-risk myelodysplastic syndrome live longer and feel better.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT04047641

• Ruxolitinib plus venetoclax, with or without azacitidine, for relapsed or refractory AML

  This phase 1 trial tests whether adding ruxolitinib to venetoclax, with or without azacitidine, is safe and helps adults whose AML has returned or not responded to prior treatment.

  Recruiting at 3 sites Phase 1 OHSU Knight Cancer Institute · Columbus, Ohio and 2 other locations · NCT03874052

• Using enasidenib and azacitidine to treat patients with recurrent or refractory acute myeloid leukemia and IDH2 gene mutation

  This study is testing if a combination of two medications, enasidenib and azacitidine, can help people with recurrent or hard-to-treat acute myeloid leukemia that has an IDH2 gene mutation.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT03683433

• Using a radioactive antibody followed by stem cell transplant to treat high-risk leukemia or myelodysplastic syndrome

  This study is testing a new radioactive treatment combined with a stem cell transplant to see if it can help people with high-risk leukemia or myelodysplastic syndrome feel better and improve their chances of recovery.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT03670966

• Using edetate calcium disodium or succimer to treat acute myeloid leukemia or myelodysplastic syndrome during chemotherapy

  This study is testing whether two drugs, edetate calcium disodium and succimer, can safely help people with acute myeloid leukemia or myelodysplastic syndrome feel better during chemotherapy.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT03630991

• Treatment for relapsed or refractory acute myeloid leukemia using a combination of chemotherapy drugs

  This study is testing a new combination of chemotherapy drugs to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia get better.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT03629171

• Combining Ivosidenib and Venetoclax with or without Azacitidine for treating IDH1 mutated blood cancers

  This study is testing a combination of two drugs, ivosidenib and venetoclax, with or without azacitidine, to see if it helps people with certain types of blood cancers that have an IDH1 mutation.

  Recruiting at 4 sites Phase 1/2 M.D. Anderson Cancer Center · Boston, Massachusetts and 3 other locations · NCT03471260

• Combining venetoclax with chemotherapy for treating acute myeloid leukemia

  This study is testing if combining a drug called venetoclax with chemotherapy can help people with newly diagnosed or tough-to-treat acute myeloid leukemia feel better and improve their chances of recovery.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT03214562

• Using radioactive treatment before stem cell transplant for high-risk leukemia patients

  This study is testing a new radioactive treatment given before a stem cell transplant to see if it can help high-risk leukemia patients by targeting cancer cells while protecting healthy ones.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT03128034

• Vaccine treatment for relapsed or refractory blood cancers

  This study is testing a new vaccine treatment for people with relapsed or hard-to-treat blood cancers to see if it can help them feel better and live longer.

  Recruiting at 2 sites Phase 1 Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT03017820

• Combining cladribine, idarubicin, cytarabine, and venetoclax for treating certain blood cancers

  This study is testing a new combination of four medications to see if it helps people with certain types of blood cancers feel better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT02115295

NIH-funded research (3)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Targeting FLT3 in relapsed or hard-to-treat acute myeloid leukemia

  This project develops immune-cell therapies that aim to attack the FLT3 protein on leukemia cells for people with relapsed or treatment-resistant acute myeloid leukemia.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-11172241

• Targeting a specific protein to treat a type of blood cancer

  This study is testing a new treatment for acute myeloid leukemia (AML) using specially designed immune cells that can find and fight cancer cells with a specific protein, aiming to improve survival for patients like you.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-10894216

• Combining Ceraxa and Vinblastine to treat difficult cases of Acute Myeloid Leukemia

  This study is looking at how well a new treatment called Ceraxa works with Vinblastine for people with relapsed or hard-to-treat Acute Myeloid Leukemia (AML), to find the best dose and help fight cancer cells while keeping side effects low.

  NIH research Keystone Nano, INC. · State College, UNITED STATES · NIH-10704116

Related topics

Quick answers

How many Refractory Acute Myeloid Leukemia clinical trials are recruiting right now?

40, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 3 countries. The most sites are in United States (35 trials), China (4 trials), Russia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 21, Phase 1/2: 11, Phase 2: 7, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →